MedCity Influencers, Opinion
Everything and nothing has changed: Why VC innovation and funding in digital health need to target Medicaid populations
By Justin Norden
Admittedly, Medicaid is not the market most entrepreneurs think about when starting a company for the first time, which is why it is even more critical for VCs to support these initiatives.
Pharma, BioPharma
BioMarin Pharma sees big things for first FDA-approved dwarfism drug
By Frank Vinluan
BioMarin Pharmaceutical’s Voxzogo is the first FDA approved therapy for achondroplasia, an inherited disorder that causes the most common form of dwarfism. With approvals in Europe and the U.S., and more regulatory decisions expected in 2022, the biotech said the drug has blockbuster potential.
—ADVERTISEMENT—
Knowledge Hub
eBook
eBook
eBook
Retail Health, Health Services, Pharmacy
Walgreens bets all its chips on a new healthcare strategy. Will patients buy in?
By Elise Reuter
The company launched a new health division, and has doubled down on its plans to open primary care clinics with VillageMD. It faces big competitors in CVS and Walmart, and it’ll take time to see if its new strategy pays off.
Artificial Intelligence, BioPharma
Sanofi makes $270M bet that a startup’s AI tech can boost its cancer drug R&D
By Frank Vinluan
The sum represents Sanofi’s equity investment in Owkin, plus a payment to begin a research partnership covering four types of cancer. Meanwhile, Owkin said the Sanofi investment boosts the startup into unicorn status and marks the start of its Series B funding round.
Health IT, MedCity Influencers
Digital identity: The key to consumer-driven healthcare
By Kristen Valdes
Digital identity proofing via mobile phone or desktop enables consumers to take personal control of their identity, solving many of the frustrations that occur during care interactions, including everything from redundant paper forms to registration and wait times.
Artificial Intelligence, BioPharma
Generate Bio adds $370M for big push toward programmable protein medicines
By Frank Vinluan
Generate Biomedicines applies artificial intelligence and machine learning to protein analysis, which it uses to program its protein therapies for particular applications. The startup now has $370 million in financing to rapidly scale up operations, with a goal of reaching the clinic within two years.
https://medcitynews.com/
